Rasmus Hvidbjerg Gantzel

Dr. Rasmus Hvidbjerg Gantzel

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
MNMarlene Nielsen
Marlene Nielsen
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
JCJoan Clària
Joan Clària
JTJonel Trebicka
Jonel Trebicka
HMHolger Jon Møller
Holger Jon Møller
Henning GrønbækHenning Grønbæk
Henning Grønbæk
Macrophages facilitate essential homeostatic functions e.g., endocytosis, phagocytosis, and signaling during inflammation, and express a variety of scavenger receptors including CD163 and CD206, which are upregulated in response to inflammation. In healthy individuals, soluble forms of CD163 and CD206 are constitutively shed from macrophages, however, during inflammation pathogen- and damage-associated stimuli induce this shedding. Activation of resident liver macrophages viz. Kupffer cells is part of the inflammatory cascade occurring in acute and chronic liver diseases. We here review the existing literature on sCD163 and sCD206 function and shedding, and potential as biomarkers in acute and chronic liver diseases with a particular focus on Acute-on-Chronic Liver Failure (ACLF). In multiple studies sCD163 and sCD206 are elevated in relation to liver disease severity and established as reliable predictors of morbidity and mortality. However, differences in expression- and shedding-stimuli for CD163 and CD206 may explain dissimilarities in prognostic utility in patients with acute decompensation of cirrhosis and ACLF.

1 December 2023 in Hepatology Communications
Verified
Journal Article
Open access
TKThit M. Kronborg
Thit M. Kronborg
RSRobert Schierwagen
Robert Schierwagen
KTKajetan Trošt
Kajetan Trošt
QGQian Gao
Qian Gao
TMThomas Moritz
Thomas Moritz
NKNina Kimer
Nina Kimer
Background: Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications and mortality. We aimed to investigate the effects of atorvastatin on hospital admissions, mortality, inflammation, and lipidomics in cirrhosis with portal hypertension. Methods: We performed a double-blinded, randomized, placebo-controlled clinical trial among patients with cirrhosis and portal hypertension. Atorvastatin (10–20 mg/d) was administered for 6 months. We measured splanchnic hemodynamics, analyzed inflammatory markers, and performed lipidomics at baseline and after 6 months. Results: Seventy-eight patients were randomized, with 38 patients allocated to atorvastatin and 40 patients to placebo. Fifty-nine patients completed 6 months of intervention. Comparisons between changes in each group were calculated. Liver-related complications and mortality were similar between the groups. The HVPG and Model for End-stage Liver Disease score did not change between groups (p=0.95 and 0.87, respectively). Atorvastatin decreased 3 of 42 inflammatory markers, CD62-L-selectin, matrix metalloproteinases-2, and TNF-α (p-values: 0.005, 0.011, and 0.023, respectively), while lipidomics was not significantly changed. Conclusions: In patients with cirrhosis, atorvastatin was safe to use, but did not reduce mortality, the risk of liver-related complications, or the HVPG. Atorvastatin induced minor anti-inflammatory effects and minor effects on lipids during a 6-month treatment period.

5 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
LMLouise S. Mogensen
Louise S. Mogensen
SMStine A. Mikkelsen
Stine A. Mikkelsen
BVBente Vilsen
Bente Vilsen
RMRobert S. Molday
Robert S. Molday
JAJens Peter Andersen
Jens Peter Andersen
Phospholipid flippases (P4-ATPases) translocate specific phospholipids from the exoplasmic to the cytoplasmic leaflet of membranes. While there is good evidence that the overall molecular structure of flippases is similar to that of P-type ATPase ion-pumps, the transport pathway for the “giant” lipid substrate has not been determined. ATP8A2 is a flippase with selectivity toward phosphatidylserine (PS), possessing a net negatively charged head group, whereas ATP8B1 exhibits selectivity toward the electrically neutral phosphatidylcholine (PC). Setting out to elucidate the functional consequences of flippase disease mutations, we have identified residues of ATP8A2 that are critical to the interaction with the lipid substrate during the translocation process. Among the residues pinpointed are I91 and L308, which are positioned near proposed translocation routes through the protein. In addition we pinpoint two juxtaposed oppositely charged residues, E897 and R898, in the exoplasmic loop between transmembrane helices 5 and 6. The glutamate is conserved between PS and PC flippases, whereas the arginine is replaced by a negatively charged aspartate in ATP8B1. Our mutational analysis suggests that the glutamate repels the PS head group, whereas the arginine minimizes this repulsion in ATP8A2, thereby contributing to control the entry of the phospholipid substrate into the translocation pathway.

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
FKFrederik Kraglund
Frederik Kraglund
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
PJPeter Jepsen
Peter Jepsen
NANiels Kristian Aagaard
Niels Kristian Aagaard

1 December 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
Henning GrønbækHenning Grønbæk
Henning Grønbæk
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
TLTea Lund Laursen
Tea Lund Laursen
KKKonstantin Kazankov
Konstantin Kazankov
HMHolger Jon Møller
Holger Jon Møller

16 August 2022 in Hepatology Communications
Verified
Journal Article
Open access
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
NANiels Kristian Aagaard
Niels Kristian Aagaard
HVHendrik Vilstrup
Hendrik Vilstrup
HWHugh Robert WATSON
Hugh Robert WATSON
Henning GrønbækHenning Grønbæk
Henning Grønbæk
PJPeter Jepsen
Peter Jepsen
Ascites formation is a sign of decompensation of cirrhosis and heralds a poor prognosis. The widely used standard binary classification of ascites as diuretic‐responsive or refractory does not cover the spectrum of ascites and has limited prognostic information. We developed the Cirrhotic Ascites Severity (CIRAS) model to predict 1‐year mortality among 465 patients randomized to placebo in the satavaptan trials investigating treatment of cirrhotic ascites. We used multivariable logistic regression to derive the CIRAS model based on these variables: ascites discomfort score (≤50 or >50), plasma sodium (≥140, 133–139, 125–132, or <125 mmoL/L), and a composite of ascites accumulation and diuretic treatment. We validated the prediction model in 697 trial participants randomized to satavaptan treatment. The 1‐year all‐cause mortality was 19.6%. The area under the receiver operator curve was higher for the CIRAS model than for the standard ascites classification into refractory and diuretic‐responsive in both the development cohort (0.68 [95% confidence interval (CI): 0.62–0.75] vs. 0.62 [0.57–0.68]), and the validation cohort (0.68 [0.64–0.72] vs. 0.55 [0.51–0.60]). The CIRAS model had similar discrimination to the Child‐Pugh score and nearly as good as the Model for End‐Stage Liver Disease (MELD), MELD‐Na, and MELD 3.0. Conclusions: The CIRAS model based on simple ascites‐relevant data is an easily applicable and patient‐centered way to describe the severity and prognosis of all ascites grades. It carries more prognostic information than today's label of “refractory ascites” and forms the basis for earlier and better clinical decisions related to ascites management.